scispace - formally typeset
Search or ask a question
Institution

International Agency for Research on Cancer

GovernmentLyon, France
About: International Agency for Research on Cancer is a government organization based out in Lyon, France. It is known for research contribution in the topics: Population & Cancer. The organization has 2989 authors who have published 9010 publications receiving 929752 citations. The organization is also known as: IARC.


Papers
More filters
Journal ArticleDOI
TL;DR: In this article, the authors conducted a meta-analysis of reported studies on the accuracy to detect high grade cervical intra-epithelial neoplasia or worse disease (CIN2+) in women with ASCUS or LSIL.

202 citations

Journal ArticleDOI
01 Nov 1995-Glia
TL;DR: The hypothesis that p53 mutations can give rise to loss of tumor suppressor functions as well as to gain of oncogenic transformation capabilities is proposed.
Abstract: Mutation of the p53 gene is among the most common lesions in a variety of human tumors, including those of the central nervous system. In most instances, mutation of one p53 allele is followed by loss of the remaining wild-type allele, resulting in cells with a complete absence of functional wild-type p53 protein. However, in some situations, such as at initiation of spontaneously arising gliomas or as the germline configuration of patients with the Li-Fraumeni syndrome, cells clearly carry both wild-type and mutant p53 alleles. These observations lead to the hypothesis that p53 mutations can give rise to loss of tumor suppressor functions as well as to gain of oncogenic transformation capabilities. In this review, we define the types of mutations that occur in the p53 gene in various glial tumors, contrast that with the spectra described in other human tumor types, and discuss the biochemistry and physiology of the p53 protein and its ability to regulate and be regulated by other gene products. We use this information to propose roles for p53 in the initiation and progression of human gliomas.

201 citations

Journal ArticleDOI
TL;DR: High circulating adiponectin levels are associated with reduced endometrial cancer risk, largely independent of other obesity-related risk factors.
Abstract: Background: Adiponectin, an adipocytokine secreted by adipose tissue, is decreased in obesity, insulin resistance, type 2 diabetes, and polycystic ovary syndrome, all of which are well-established risk factors for endometrial cancer. Methods: We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition to examine the relation between prediagnostic plasma adiponectin levels and endometrial cancer risk. Among pre- and postmenopausal women who were not currently using exogenous hormones, 284 women developed incident endometrial cancer during an average of 5.1 yr of follow-up. Using risk set sampling, 548 control subjects were selected, matched on center, age, menopausal status, phase of menstrual cycle, time of blood draw, and fasting status. Conditional logistic regression models were used to estimate relative risks and 95% confidence intervals. Results: Adiponectin levels were inversely associated with endometrial cancer risk [body mass index-adjusted rel...

201 citations

Journal ArticleDOI
TL;DR: A substantial number of cancer cases are attributable to diabetes and high BMI, and clinical and public health efforts should focus on identifying optimal preventive and screening measures for whole populations and individual patients.

201 citations

Journal ArticleDOI
TL;DR: Irrespective of BMI, metabolically unhealthy individuals had higher CHD risk than their healthy counterparts and population-wide strategies to tackle obesity are challenged, challenging the concept of 'metabolically healthy obesity.
Abstract: EPIC-CVD has been supported by the European Union Framework 7 (HEALTH-F2-2012-279233), the European Research Council (268834), the UK Medical Research Council (G0800270 and MR/L003120/1), the British Heart Foundation (SP/09/002 and RG/08/014 and RG13/13/30194), and the UK National Institute of Health Research. EPIC Asturias was also supported by the Regional Government of Asturias. EPIC-Greece is also supported by the Hellenic Health Foundation. EPIC- Heidelberg was also supported by the German Cancer Aid, German Cancer Research Centre, German Federal Ministry of Education and Research. EPIC-Oxford was also supported by the UK Medical Research Council (MR/M012190/1) and Cancer Research UK (570/A16491). EPIC-Ragusa was also supported by the Sicilian Government, AIRE ONLUS Ragusa, and AVIS Ragusa. EPIC-Turin was supported also by the Compagnia di San Paolo and the Human Genetics Foundation-Torino (HuGeF).

201 citations


Authors

Showing all 3012 results

NameH-indexPapersCitations
David J. Hunter2131836207050
Kay-Tee Khaw1741389138782
Elio Riboli1581136110499
Silvia Franceschi1551340112504
Stephen J. Chanock1541220119390
Paolo Boffetta148145593876
Timothy J. Key14680890810
Hans-Olov Adami14590883473
Joseph J.Y. Sung142124092035
Heiner Boeing140102492580
Anne Tjønneland139134591556
Kim Overvad139119686018
Sheila Bingham13651967332
Pasi A. Jänne13668589488
Peter Kraft13582182116
Network Information
Related Institutions (5)
German Cancer Research Center
26.3K papers, 1.4M citations

92% related

Fred Hutchinson Cancer Research Center
30.9K papers, 2.2M citations

89% related

University of Texas MD Anderson Cancer Center
92.5K papers, 4.7M citations

89% related

National Institutes of Health
297.8K papers, 21.3M citations

88% related

Memorial Sloan Kettering Cancer Center
65.3K papers, 4.4M citations

88% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20238
202233
2021483
2020495
2019423
2018400